Study · Randomized controlled trial · 2021

8 results

Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial.

Giles J, Alama P, Gamiz P, Vidal C, Badia P, Pellicer A, Bosch E

Fertility and sterility2 Apr 2021Cited by 52 (Europe PMC)

PMID33814126DOI10.1016/j.fertnstert.2021.02.036PepBankPUB-33814126

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In oocyte donors, retrieved oocytes were 21.2 ± 9.2 with ganirelix versus 21.4 ± 11.7 with MPA (MPA-minus-ganirelix difference 0.14, 95% CI -2.233, 2.517).
In plain wordsIn oocyte donors, ganirelix and MPA produced similar egg retrieval numbers.
Peptide
Ganirelix
Outcome
Direction not reportedRetrieved oocytes
Study
n: not reported in source
Comparator
Medroxyprogesterone acetate
Analysis
Primary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/dayAs given in this study (human).
Measurements
Retrieved oocytes, mean
21.4 oocytes
MPA group; SD 11.7
Retrieved oocytes, mean
21.2 oocytes
antagonist group; SD 9.2
Mean difference in retrieved oocytes
0.14 oocytes
MPA minus antagonist; 95% CI -2.233 to 2.517
Source sentences
Summary
The number of oocytes retrieved was 21.4 ± 11.7 in the MPA group and 21.2 ± 9.2 in the antagonist group (mean difference 0.14; 95% confidence interval -2.233, 2.517).
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective, randomized, controlled trial of cycles was conducted from October 2017 to June 2019 to evaluate ovarian response in terms of the number of oocytes.
Summary · context
One hundred sixty-one donors were treated with a daily dose of 10 mg of MPA administered orally from the beginning of ovarian stimulation (OS), and 156 were treated with a GnRH antagonist (initiated once the leading follicle reached a diameter of 13 mm).
Summary · context
A short protocol with ganirelix at 0.25 mg/day was used for the control group.
Report a problemFND-3381412601
02HumanRandomized controlled trialEfficacy outcome
In oocyte donors, ganirelix and MPA had comparable gonadotropin dose, stimulation duration, and serum and follicular-fluid endocrine profiles.
In plain wordsIn oocyte donors, ganirelix and MPA had similar stimulation requirements and hormone profiles.
Peptide
Ganirelix
Outcome
Direction not reportedGonadotropin dose, stimulation duration and endocrine profiles
Study
n: not reported in source
Comparator
Medroxyprogesterone acetate
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/dayAs given in this study (human).
Source sentences
Summary
The total dose of recombinant follicle-stimulating hormone, duration of OS, and endocrine profiles of the serum and follicular fluids were comparable in the 2 groups.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective, randomized, controlled trial of cycles was conducted from October 2017 to June 2019 to evaluate ovarian response in terms of the number of oocytes.
Summary · context
One hundred sixty-one donors were treated with a daily dose of 10 mg of MPA administered orally from the beginning of ovarian stimulation (OS), and 156 were treated with a GnRH antagonist (initiated once the leading follicle reached a diameter of 13 mm).
Summary · context
A short protocol with ganirelix at 0.25 mg/day was used for the control group.
Report a problemFND-3381412602
03HumanRandomized controlled trialEfficacy outcome
In oocyte donors, no early ovulation occurred with either ganirelix or MPA.
In plain wordsIn oocyte donors, neither ganirelix nor MPA groups had early ovulation.
Peptide
Ganirelix
Outcome
No significant changeEarly ovulation
Study
n: not reported in source
Comparator
Medroxyprogesterone acetate
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/dayAs given in this study (human).
Source sentences
Summary
No early ovulation was observed in either group.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective, randomized, controlled trial of cycles was conducted from October 2017 to June 2019 to evaluate ovarian response in terms of the number of oocytes.
Summary · context
One hundred sixty-one donors were treated with a daily dose of 10 mg of MPA administered orally from the beginning of ovarian stimulation (OS), and 156 were treated with a GnRH antagonist (initiated once the leading follicle reached a diameter of 13 mm).
Summary · context
A short protocol with ganirelix at 0.25 mg/day was used for the control group.
Report a problemFND-3381412603
04HumanObservational studyEfficacy outcome
In recipients of donated oocytes, implantation rates did not differ significantly: 62% with ganirelix donor treatment versus 68.1% with MPA.
In plain wordsIn donated-egg recipients, implantation rates were similar after ganirelix or MPA donor treatment.
Peptide
Ganirelix
Outcome
No significant changeImplantation rate
Study
n: not reported in source
Comparator
Medroxyprogesterone acetate
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/dayAs given in this study (human).
Measurements
Implantation rate
68.1%
MPA group
Implantation rate
62%
antagonist (ganirelix) group
Source sentences
Summary
No statistically significant differences with respect to implantation rate (68.1% in the MPA group vs. 62% in the antagonist group)
4 context sentences(design, population, supporting numbers)
Summary · context
The reproductive outcomes of the recipients were retrospectively analyzed later.
Summary · context
A prospective, randomized, controlled trial of cycles was conducted from October 2017 to June 2019 to evaluate ovarian response in terms of the number of oocytes.
Summary · context
One hundred sixty-one donors were treated with a daily dose of 10 mg of MPA administered orally from the beginning of ovarian stimulation (OS), and 156 were treated with a GnRH antagonist (initiated once the leading follicle reached a diameter of 13 mm).
Summary · context
A short protocol with ganirelix at 0.25 mg/day was used for the control group.
Report a problemFND-3381412604
05HumanObservational studyEfficacy outcome
In recipients of donated oocytes, clinical pregnancy rates did not differ significantly: 57.8 with ganirelix donor treatment versus 64.5% with MPA.
In plain wordsIn donated-egg recipients, clinical pregnancy rates were similar after ganirelix or MPA donor treatment.
Peptide
Ganirelix
Outcome
No significant changeClinical pregnancy rate
Study
n: not reported in source
Comparator
Medroxyprogesterone acetate
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/dayAs given in this study (human).
Measurements
Clinical pregnancy rate
64.5%
MPA group
Clinical pregnancy rate
57.8%
antagonist (ganirelix) group
Source sentences
Summary
clinical pregnancy rate (64.5% in the MPA group vs. 57.8 in the antagonist group)
5 context sentences(design, population, supporting numbers)
Summary · context
No statistically significant differences with respect to
Summary · context
The reproductive outcomes of the recipients were retrospectively analyzed later.
Summary · context
A prospective, randomized, controlled trial of cycles was conducted from October 2017 to June 2019 to evaluate ovarian response in terms of the number of oocytes.
Summary · context
One hundred sixty-one donors were treated with a daily dose of 10 mg of MPA administered orally from the beginning of ovarian stimulation (OS), and 156 were treated with a GnRH antagonist (initiated once the leading follicle reached a diameter of 13 mm).
Summary · context
A short protocol with ganirelix at 0.25 mg/day was used for the control group.
Report a problemFND-3381412605
06HumanObservational studyEfficacy outcome
In recipients of donated oocytes, ongoing pregnancy rates did not differ significantly: 48.5% with ganirelix donor treatment versus 55.4% with MPA.
In plain wordsIn donated-egg recipients, ongoing pregnancy rates were similar after ganirelix or MPA donor treatment.
Peptide
Ganirelix
Outcome
No significant changeOngoing pregnancy rate
Study
n: not reported in source
Comparator
Medroxyprogesterone acetate
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/dayAs given in this study (human).
Measurements
Ongoing pregnancy rate
55.4%
MPA group
Ongoing pregnancy rate
48.5%
antagonist (ganirelix) group
Source sentences
Summary
ongoing pregnancy rate (55.4% in the MPA group vs. 48.5% in the antagonist group)
5 context sentences(design, population, supporting numbers)
Summary · context
No statistically significant differences with respect to
Summary · context
The reproductive outcomes of the recipients were retrospectively analyzed later.
Summary · context
A prospective, randomized, controlled trial of cycles was conducted from October 2017 to June 2019 to evaluate ovarian response in terms of the number of oocytes.
Summary · context
One hundred sixty-one donors were treated with a daily dose of 10 mg of MPA administered orally from the beginning of ovarian stimulation (OS), and 156 were treated with a GnRH antagonist (initiated once the leading follicle reached a diameter of 13 mm).
Summary · context
A short protocol with ganirelix at 0.25 mg/day was used for the control group.
Report a problemFND-3381412606
07HumanObservational studyEfficacy outcome
In recipients of donated oocytes, live birth rates did not differ significantly: 48.5% with ganirelix donor treatment versus 55.1% with MPA.
In plain wordsIn donated-egg recipients, live birth rates were similar after ganirelix or MPA donor treatment.
Peptide
Ganirelix
Outcome
No significant changeLive birth rate
Study
n: not reported in source
Comparator
Medroxyprogesterone acetate
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/dayAs given in this study (human).
Measurements
Live birth rate
55.1%
MPA group
Live birth rate
48.5%
antagonist (ganirelix) group
Source sentences
Summary
live birth rate (55.1% in the MPA group vs. 48.5% in the antagonist group)
5 context sentences(design, population, supporting numbers)
Summary · context
No statistically significant differences with respect to
Summary · context
The reproductive outcomes of the recipients were retrospectively analyzed later.
Summary · context
A prospective, randomized, controlled trial of cycles was conducted from October 2017 to June 2019 to evaluate ovarian response in terms of the number of oocytes.
Summary · context
One hundred sixty-one donors were treated with a daily dose of 10 mg of MPA administered orally from the beginning of ovarian stimulation (OS), and 156 were treated with a GnRH antagonist (initiated once the leading follicle reached a diameter of 13 mm).
Summary · context
A short protocol with ganirelix at 0.25 mg/day was used for the control group.
Report a problemFND-3381412607
08HumanObservational studyEfficacy outcome
In recipients of donated oocytes, cumulative live birth rates did not differ significantly: 70.7% with ganirelix donor treatment versus 73.8% with MPA.
In plain wordsIn donated-egg recipients, cumulative live birth rates were similar after ganirelix or MPA donor treatment.
Peptide
Ganirelix
Outcome
No significant changeCumulative live birth rate
Study
n: not reported in source
Comparator
Medroxyprogesterone acetate
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/dayAs given in this study (human).
Measurements
Cumulative live birth rate
73.8%
MPA group
Cumulative live birth rate
70.7%
antagonist (ganirelix) group
Source sentences
Summary
cumulative live birth rate (73.8% in the MPA group vs. 70.7% in the antagonist group) were observed between the groups.
5 context sentences(design, population, supporting numbers)
Summary · context
No statistically significant differences with respect to
Summary · context
The reproductive outcomes of the recipients were retrospectively analyzed later.
Summary · context
A prospective, randomized, controlled trial of cycles was conducted from October 2017 to June 2019 to evaluate ovarian response in terms of the number of oocytes.
Summary · context
One hundred sixty-one donors were treated with a daily dose of 10 mg of MPA administered orally from the beginning of ovarian stimulation (OS), and 156 were treated with a GnRH antagonist (initiated once the leading follicle reached a diameter of 13 mm).
Summary · context
A short protocol with ganirelix at 0.25 mg/day was used for the control group.
Report a problemFND-3381412608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT06637189

Protocol with Progestin-primed Ovarian Stimulation (PPOS) from the Beginning of Stimulation Versus Protocol with GnRH Antagonists for Ovarian Stimulation in Patients Undergoing DUOSTIM with Embryo Accumulation for PGT-A.

Ginefivn = 144est. 15 Oct 2024 to est. 31 Dec 2025

Stimulation in the Ovary · Embryo · Oocyte · Oocyte Retrieval · Fertilization in Vitro · Blastocyst · PGT-A

Trial page ClinicalTrials.govUpdated 15 Oct 2024

CompletedPhase 4NCT05954962

Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation.

Instituto Bernabeun = 15023 Dec 2023 to 30 Aug 2025

IVF

Trial page ClinicalTrials.govUpdated 27 Mar 2026

CompletedPhase 3NCT03300960

Usefulness of Medroxyprogesterone Acetate in Follicular Phase in Oocyte Donors. Undergoing Ovarian Stimulation

Instituto Valenciano de Infertilidad, IVI VALENCIAn = 31820 Oct 2017 to 25 Jun 2019

Infertility

Trial page ClinicalTrials.govUpdated 25 Aug 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.